Selected Publications

Academic Article

Year Title Altmetric
2021 Neurodegenerative VPS41 variants inhibit HOPS function and mTORC1-dependent TFEB/TFE3 regulationEMBO Molecular Medicine.  13. 2021
2021 A conformational switch driven by phosphorylation regulates the activity of the evolutionarily conserved SNARE Ykt6 2021
2021 Conserved nicotine-activated neuroprotective pathways involve mitochondrial stressiScience.  24. 2021
2020 Therapeutic genetic variation revealed in diverse Hsp104 homologseLife.  9:1-52. 2020
2020 Modeling neurodegeneration in Caenorhabditis elegans 2020
2019 Cyclized NDGA modifies dynamic α-synuclein monomers preventing aggregation and toxicityScientific Reports.  9. 2019
2019 Genetic defects in mitochondrial dynamics in caenorhabditis elegans impact ultraviolet c radiation- and 6-hydroxydopamine-induced neurodegenerationInternational Journal of Molecular Sciences.  20. 2019
2019 Vacuolar protein sorting protein 41 (VPS41) at an intersection of endosomal traffic in neurodegenerative diseaseNeural Regeneration Research.  14:1210-1212. 2019
2019 Found in translation: The utility of C. elegans Alpha-Synuclein models of Parkinson’s diseaseBrain Sciences.  9. 2019
2019 ApoE-associated modulation of neuroprotection from Aβ-mediated neurodegeneration in transgenic Caenorhabditis elegans 2019
2018 Distinct functional roles of Vps41-mediated neuroprotection in Alzheimer's and Parkinson's disease models of neurodegenerationHuman Molecular Genetics.  27:4176-4193. 2018
2018 No country for old worms: A systematic review of the application of C. elegans to investigate a bacterial source of environmental neurotoxicity in parkinson’s diseaseMetabolites.  8. 2018
2018 Correction to: The Small GTPase RAC1/CED-10 Is Essential in Maintaining Dopaminergic Neuron Function and Survival Against α-Synuclein-Induced Toxicity (Molecular Neurobiology, (2018), 55, 9, (7533-7552), 10.1007/s12035-018-0881-7)Molecular Neurobiology.  55:7553-7554. 2018
2018 The Small GTPase RAC1/CED-10 Is Essential in Maintaining Dopaminergic Neuron Function and Survival Against α-Synuclein-Induced ToxicityMolecular Neurobiology.  55:7533-7552. 2018
2018 Alpha-synuclein inhibits Snx3-retromer-mediated retrograde recycling of iron transporters in S. cerevisiae and C. elegans models of Parkinson's diseaseHuman Molecular Genetics.  27:1514-1532. 2018
2018 Gene-by-environment interactions that disrupt mitochondrial homeostasis cause neurodegeneration in C. elegans Parkinson's modelsCell Death and Disease.  9. 2018
2017 Genetic and Pharmacological Discovery for Alzheimer's Disease Using Caenorhabditis elegansACS Chemical Neuroscience.  8:2596-2606. 2017
2017 Dysregulation of the mitochondrial unfolded protein response induces non-apoptotic dopaminergic neurodegeneration in C. Elegans models of parkinson’s disease 2017
2017 NCEH-1 modulates cholesterol metabolism and protects against α-synuclein toxicity in a C. elegans model of Parkinson's diseaseHuman Molecular Genetics.  26:3823-3836. 2017
2017 Dihydropyrimidine-Thiones and Clioquinol Synergize to Target β-Amyloid Cellular Pathologies through a Metal-Dependent MechanismACS Chemical Neuroscience.  8:2039-2055. 2017
2017 C. elegans as a model system to accelerate discovery for Parkinson diseaseCurrent Opinion in Genetics and Development.  44:102-109. 2017
2017 Meet our editorial board memberCurrent Neuropharmacology.  15:195. 2017
2017 Dopamine induces soluble α-synuclein oligomers and nigrostriatal degenerationNature Neuroscience.  20:1560-1568. 2017
2016 Chemical compensation of mitochondrial phospholipid depletion in yeast and animal models of Parkinson's diseasePLoS ONE.  11. 2016
2015 A bacterial metabolite induces glutathione-tractable proteostatic damage, proteasomal disturbances, and PINK1-dependent autophagy in C. elegansCell Death and Disease.  6. 2015
2015 Glutaredoxin deficiency exacerbates neurodegeneration in C. Elegans models of Parkinson's diseaseHuman Molecular Genetics.  24:1322-1335. 2015
2015 Phenazine derivatives cause proteotoxicity and stress in C. elegansNeuroscience Letters.  584:23-27. 2015
2014 RTCB-1 mediates neuroprotection via XBP-1 mRNA splicing in the unfolded protein response pathway 2014
2014 Phosphatidylethanolamine deficiency disrupts α-synuclein homeostasis in yeast and worm models of Parkinson disease 2014
2014 Calcineurin determines toxic versus beneficial responses to α-synuclein 2014
2014 The glycolytic enzyme, GPI, is a functionally conserved modifier of dopaminergic neurodegeneration in Parkinson's modelsCell Metabolism.  20:145-157. 2014
2014 Clioquinol promotes the degradation of metal-dependent amyloid-ß (Aß) oligomers to restore endocytosis and ameliorate Aß toxicity 2014
2014 The effects of pdr1, djr1.1 and pink1 loss in manganese-induced toxicity and the role of α-synuclein in C. elegans 2014
2014 TorsinA rescues ER-associated stress and locomotive defects in C. elegans models of ALS 2014
2014 Protective Role of DNJ-27/ERdj5 in Caenorhabditis elegans models of human neurodegenerative diseasesAntioxidants and Redox Signaling.  20:217-235. 2014
2014 Mitochondrial dysfunction, oxidative stress, and neurodegeneration elicited by a bacterial metabolite in a C. elegans Parkinson's modelCell Death and Disease.  5. 2014
2014 Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding eventsCell.  156:170-182. 2014
2013 Lysosomal impairment in Parkinson's diseaseMovement Disorders.  28:725-732. 2013
2013 Valproic acid ameliorates C. elegans dopaminergic neurodegeneration with implications for ERK-MAPK signalingNeuroscience Letters.  541:116-119. 2013
2013 Invertebrate models of dystoniaCurrent Neuropharmacology.  11:16-29. 2013
2013 Yeast reveal a "druggable" Rsp5/Nedd4 network that ameliorates α-Synuclein toxicity in neuronsScience.  342:979-983. 2013
2012 Identification of novel ATP13A2 interactors and their role in α-synuclein misfolding and toxicityHuman Molecular Genetics.  21:3785-3794. 2012
2012 A Predictable Worm: Application of Caenorhabditis elegans for Mechanistic Investigation of Movement DisordersNeurotherapeutics.  9:393-404. 2012
2012 The early-onset torsion dystonia-associated protein, torsinA, is a homeostatic regulator of endoplasmic reticulum stress responseHuman Molecular Genetics.  21:1201. 2012
2012 Functional analysis of VPS41-mediated neuroprotection in Caenorhabditis elegans and mammalian models of Parkinson's disease 2012
2012 Different 8-hydroxyquinolines protect models of TDP-43 protein, α-synuclein, and polyglutamine proteotoxicity through distinct mechanismsJournal of Biological Chemistry.  287:4107-4120. 2012
2011 Functional links between Aβ toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeastScience.  334:1241-1245. 2011
2011 Methodological strategies to evaluate functional effectors related to parkinson's disease through application of caenorhabditis elegans modelsNeuromethods.  61:31-53. 2011
2011 Modeling dopamine neuron degeneration in caenorhabditis elegansMethods in Molecular Biology.  793:129-148. 2011
2011 Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease modelsHuman Molecular Genetics.  20:3933-3942. 2011
2011 TorsinA participates in endoplasmic reticulum-associated degradationNature Communications.  2. 2011
2011 Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathiesCell.  146:37-52. 2011
2011 Cell culture to investigate neurotoxicity and neurodegeneration utilizing Caenorhabditis elegansNeuromethods.  56:129-143. 2011
2011 Caenorhabditis elegans as a model system for identifying effectors of α-synuclein misfolding and dopaminergic cell death associated with Parkinson's diseaseMethods.  53:220-225. 2011
2010 The early-onset torsion dystonia-associated protein, torsinA, displays molecular chaperone activity in vitroCell Stress and Chaperones.  15:605-617. 2010
2010 Disinfecting dystonia? Drug discovery using worms identifies an antibiotic as a neuroprotective lead molecule for movement disordersFuture Neurology.  5:473-476. 2010
2010 The early-onset torsion dystonia-associated protein, torsinA, is a homeostatic regulator of endoplasmic reticulum stress responseHuman Molecular Genetics.  19:3502-3515. 2010
2010 C. elegans as a model organism to investigate molecular pathways involved with Parkinson's diseaseDevelopmental Dynamics.  239:1282-1295. 2010
2010 Chemical enhancement of torsinA function in cell and animal models of torsion dystonia 2010
2010 Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models 2010
2010 VPS41, a protein involved in lysosomal trafficking, is protective in Caenorhabditis elegans and mammalian cellular models of Parkinson's diseaseNeurobiology of Disease.  37:330-338. 2010
2010 Differential neuroprotective effects of 14-3-3 proteins in models of Parkinson's diseaseCell Death and Disease.  1. 2010
2010 Low-dose bafilomycin attenuates neuronal cell death associated with autophagy-lysosome pathway dysfunctionJournal of Neurochemistry.  114:1193-1204. 2010
2009 Pharmacogenetic analysis reveals a post-developmental role for Rac GTPases in Caenorhabditis elegans GABAergic neurotransmission 2009
2009 Investigating bacterial sources of toxicity as an environmental contributor to dopaminergic neurodegenerationPLoS ONE.  4. 2009
2009 α-Synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicityNature Genetics.  41:308-315. 2009
2009 Rapid selection of cyclic peptides that reduce α-synuclein toxicity in yeast and animal modelsNature Chemical Biology.  5:655-663. 2009
2009 The microtubule-associated protein, NUD-1, exhibits chaperone activity in vitroCell Stress and Chaperones.  14:95-103. 2009
2008 Traversing a wormhole to combat Parkinson's disease 2008
2008 Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson's diseaseNeuroscience Letters.  439:129-133. 2008
2008 Hypothesis-based RNAi screening identifies neuroprotective genes in a Parkinson's disease model 2008
2008 The Parkinson's disease protein α-synuclein disrupts cellular Rab homeostasis 2008
2008 Animal models for drug discovery in dystoniaExpert Opinion on Drug Discovery.  3:83-97. 2008
2008 Application of a C. elegans dopamine neuron degeneration assay for the validation of potential parkinson's disease genesJournal of Visualized Experiments2008
2008 Generation of stable transgenic C. elegans using microinjectionJournal of Visualized Experiments2008
2008 Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity.Molecular Brain.  1:17. 2008
2008 Paradigms for pharmacological characterization of C. elegans synaptic transmission mutantsJournal of Visualized Experiments2008
2007 Ubiquitin conjugating enzymes participate in polyglutamine protein aggregationBMC Cell Biology.  8. 2007
2006 Genetic interactions among cortical malformation genes that influence susceptibility to convulsions in C. elegansBrain Research.  1120:23-34. 2006
2006 Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species 2006
2006 α-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's modelsScience.  313:324-328. 2006
2005 Torsin-mediated protection from cellular stress in the dopaminergic neurons of Caenorhabditis elegans 2005
2004 MEC-2 is recruited to the putative mechanosensory complex in C. elegans touch receptor neurons through its stomatin-like domainCurrent Biology.  14:1888-1896. 2004
2004 Epileptic-like convulsions associated with LIS-1 in the cytoskeletal control of neurotransmitter signaling in Caenorhabditis elegansHuman Molecular Genetics.  13:2043-2059. 2004
2004 An animal model to discern torsin function: suppression of protein aggregation in C. elegans. 2004
2004 Using Caenorhabditis elegans to probe toxicity of 1-alkyl-3-methylimidazolium chloride based ionic liquidsChemical Communications.  4:668-669. 2004
2003 Role of NudC, a dynein-associated nuclear movement protein, in mitosis and cytokinesisJournal of Cell Science.  116:1991-2003. 2003
2003 Suppression of polyglutamine-induced protein aggregation in Caenorhabditis elegans by torsin proteinsHuman Molecular Genetics.  12:307-319. 2003
2001 Evolutionarily conserved nuclear migration genes required for early embryonic development in Caenorhabditis elegans 2001
1996 Genetic interactions affecting touch sensitivity in Caenorhabditis elegans 1996
1995 Fungal lipopeptide mating pheromones: A model system for the study of protein prenylationMicrobiological reviews.  59:406-422. 1995
1994 Consequences of altered isoprenylation targets on a-factor export and bioactivity 1994
1994 Candida albicans gene encoding resistance to benomyl and methotrexate is a multidrug resistance geneAntimicrobial Agents and Chemotherapy.  38:648-652. 1994
1994 Molecular determinants of bioactivity of the Saccharomyces cerevisiae lipopeptide mating pheromoneJournal of Biological Chemistry.  269:19817-19825. 1994
1993 Identification of a hyperactive mating pheromone of Saccharomyces cerevisiaeBiochemical and Biophysical Research Communications.  197:1173-1178. 1993
1991 Significance of C-terminal cysteine modifications to the biological activity of the Saccharomyces cerevisiae a-factor mating pheromoneMolecular and Cellular Biology.  11:3603-3612. 1991
1990 Total in vitro maturation of the Saccharomyces cerevisiae a-factor lipopeptide mating pheromoneBiochemical and Biophysical Research Communications.  172:1310-1316. 1990
1990 Purification, properties, and titer of a hemolymph trophic factor in larvae and pupae of Manduca sextaInsect biochemistry.  20:65-72. 1990
1989 Total synthesis of the lipopeptide a-mating factor ofSaccharomyces cerevisiaeBiochemical and Biophysical Research Communications.  162:253-257. 1989


Year Title Altmetric
2009 The nematode, Caenorhabditis elegans, as an emerging model for investigating epilepsy.  Ed. 40.  2009


Year Title Altmetric
2015 Use of Caenorhabditis elegans to Model Human Movement Disorders.  97-116. 2015
2005 Use of C. elegans to model human movement disorders.  111-126. 2005

Full Name

  • Guy Caldwell